{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10.6","upperLimit":"37.6","value":"22.0"},{"groupId":"OG001","lowerLimit":"16.6","upperLimit":"46.5","value":"30.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"40"}],"units":"Participants"}],"description":"SREs were defined according to the Bondronat Summary of Product Characteristics (SmPC) to include radiotherapy to bone for treatment of fractures/impending fractures, surgery to bone for treatment of fractures, vertebral fractures, and non-vertebral fractures. The percentage of participants with at least 1 SRE during the study was reported.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with multiple myeloma received ibandronate via 15-minute IV infusion as 6 mg every 4 weeks for up to 92 weeks. As a result of slow recruitment, the treatment duration was shortened to 40 weeks for participants who had not yet received 48 weeks of treatment. All participants returned for an additional follow-up observation 4 weeks after the end of treatment.","id":"OG000","title":"Ibandronate"},{"description":"Participants with multiple myeloma received zoledronate via 15-minute IV infusion as 4 mg every 4 weeks for up to 92 weeks. As a result of slow recruitment, the treatment duration was shortened to 40 weeks for participants who had not yet received 48 weeks of treatment. All participants returned for an additional follow-up observation 4 weeks after the end of treatment.","id":"OG001","title":"Zoledronate"}],"paramType":"NUMBER","populationDescription":"ITT Population.","reportingStatus":"POSTED","timeFrame":"From Baseline to end of study (up to Week 96)","title":"Percentage of Participants With Skeletal-Related Events (SREs)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}